Drybench Patent.
CEDAZURIDINE; DECITABINE, NDA 212576
The patents and exclusivities FDA's Orange Book lists for NDA 212576 as captured on 14 October 2026, each date named by its rule and its rows, and any rows of FDA's Paragraph IV list captured on 17 October 2026 that give this NDA's number. Listed protection is a range of dates, never one date.
FDA capture · review pending. Each row is shown as captured from FDA's Orange Book files and Paragraph IV list. Dates are FDA's own; spreadsheet day numbers are shown as dates, and a cell that cannot be read as one date is shown as written and left out of the range. Where FDA lists a *PED row without flags, its flags are read from the base row and marked so. A Paragraph IV row is placed here only by the number in its RLD/NDA cell; nothing is joined by name. How this page reads FDA's files has not been independently reviewed by a regulatory-affairs reviewer.
- Orange Book captured
- 14 October 2026
- Paragraph IV list captured
- 17 October 2026
- Last checked
- 30 October 2026
- Data-branch commit
- dadcab56563716abea6c5e31a5e1970080c778ef
Listed protection is a range of the dates FDA lists, not a forecast of market entry, and not legal, regulatory or investment advice.
Dates as listed in FDA's Orange Book capture of 14 October 2026. This page does not say whether a date has passed; compare it with today's date and FDA's current Orange Book. This page shows only what the capture of 14 October 2026 lists. It does not show patents or exclusivities listed before and since removed.
Listed protection
Listed dates run from 7 Jul 2027 to 10 Dec 2042, each by its own rule; no one date stands for this product.
- Earliest listed date
- 7 Jul 2027ODE-316 exclusivityRule R3 · Product 001
Source lines
exclusivity.txt line 1,086
- Latest listed date
- 10 Dec 2042US 12,697,347, use patentRule R1 · Product 001
Source lines
patent.txt line 14,177
- Latest substance patent
- 12 Feb 2034US 8,268,800, substance and use patentRule R1 · Product 001
Source lines
patent.txt line 14,181
- Latest listed patent
- 10 Dec 2042US 12,697,347, use patentRule R1 · Product 001
Source lines
patent.txt line 14,177
- Latest exclusivity
- 13 May 2029I-990 exclusivityRule R3 · Product 001
Source lines
exclusivity.txt line 1,085
Listed dates of other NDAs in the same years:2027202820292034204020412042
9 use-code patents, blocking the coded use only
Products
Each product number FDA lists under NDA 212576, as listed. The sections below name products by these numbers.
Product 001 · INQOVI
- Dosage form; route
- TABLET;
ORAL - Strength
- 100MG;35MG
- Approval date as listed
- 7 Jul 2020
- Type as listed
- RX
- Applicant as listed
- TAIHO ONCOLOGY INC
Listed patents
Every patent the FDA lists for this product, as the application holder submitted it, with its flags. The FDA does not verify listings.
12 entries from 12 rows as listed; rows merge only where every cell shown is the same, each with its product numbers.
US 8,618,075, use patent
patent.txt line 14,182- Expiry as listed
- 16 Oct 2028
- Rule
- R1
- Flags
- use code U-2864
- Product numbers
- 001
US 8,618,075, use patent
patent.txt line 14,183- Expiry as listed
- 16 Oct 2028
- Rule
- R1
- Flags
- use code U-2867
- Product numbers
- 001
US 9,567,363, substance patent
patent.txt line 14,184- Expiry as listed
- 16 Oct 2028
- Rule
- R1
- Flags
- substance
- Product numbers
- 001
US 8,268,800, substance and use patent
patent.txt line 14,178- Expiry as listed
- 12 Feb 2034
- Rule
- R1
- Flags
- substance · use code U-2864
- Product numbers
- 001
US 8,268,800, substance and use patent
patent.txt line 14,179- Expiry as listed
- 12 Feb 2034
- Rule
- R1
- Flags
- substance · use code U-2865
- Product numbers
- 001
US 8,268,800, substance and use patent
patent.txt line 14,180- Expiry as listed
- 12 Feb 2034
- Rule
- R1
- Flags
- substance · use code U-2866
- Product numbers
- 001
US 8,268,800, substance and use patent
patent.txt line 14,181- Expiry as listed
- 12 Feb 2034
- Rule
- R1
- Flags
- substance · use code U-2867
- Product numbers
- 001
US 12,195,496, product patent
patent.txt line 14,174- Expiry as listed
- 7 Oct 2040
- Rule
- R1
- Flags
- product
- Product numbers
- 001
US 11,963,971, product patent
patent.txt line 14,173- Expiry as listed
- 24 Feb 2041
- Rule
- R1
- Flags
- product
- Product numbers
- 001
US 12,239,653, use patent
patent.txt line 14,175- Expiry as listed
- 24 Feb 2041
- Rule
- R1
- Flags
- use code U-2865
- Product numbers
- 001
US 12,239,653, use patent
patent.txt line 14,176- Expiry as listed
- 24 Feb 2041
- Rule
- R1
- Flags
- use code U-2866
- Product numbers
- 001
US 12,697,347, use patent
patent.txt line 14,177- Expiry as listed
- 10 Dec 2042
- Rule
- R1
- Flags
- use code U-4587
- Product numbers
- 001
Listed exclusivities
Each exclusivity FDA lists for NDA 212576, with its code, FDA's definition of the code where the store's code list gives one, and its date as listed.
ODE-316 exclusivity
exclusivity.txt line 1,086- Date
- 7 Jul 2027
- Rule
- R3
- Definition
- Orphan drug exclusivity (to be checked against FDA's list)
- Product numbers
- 001
I-990 exclusivity
exclusivity.txt line 1,085- Date
- 13 May 2029
- Rule
- R3
- Definition
- New indication (to be checked against FDA's list)
- Product numbers
- 001
Paragraph IV list rows giving NDA 212576
The rows of FDA's Paragraph IV certifications list as captured on 17 October 2026 whose RLD/NDA cell gives NDA 212576, each cell as listed.
Rows with no NDA number this page can match are kept apart on the list page; some may concern this product.
No row of the Paragraph IV list captured on 17 October 2026 gives NDA 212576 in its RLD/NDA cell. This does not mean no certification was submitted or that no application challenges a patent listed here.
Notes from the trace
- R6 tentative approvals: not in the Orange Book data files as captured; the Drugs@FDA join is a later ruling.
Patents vs FDA exclusivityHow to read the Orange Book data filesParagraph IV certificationWhat changed, by week